Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 845

1.

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F.

Eur Urol. 2019 Nov 7. pii: S0302-2838(19)30825-5. doi: 10.1016/j.eururo.2019.10.026. [Epub ahead of print]

PMID:
31708296
2.

Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).

Buglione M, Noale M, Bruni A, Antonelli A, Bertoni F, Corvo' R, Ricardi U, Borghetti P, Maddalo M, Simeone C, Mazzeo E, Porreca A, Serni S, Bassi P, Gacci M, Mirone V, Montironi R, Tubaro A, Berruti A, Conti GN, Maggi S, Magrini SM, Triggiani L; Pros-IT CNR study group.

PLoS One. 2019 Nov 1;14(11):e0224151. doi: 10.1371/journal.pone.0224151. eCollection 2019.

3.

Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.

Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A.

Immunotherapy. 2019 Oct 30. doi: 10.2217/imt-2019-0115. [Epub ahead of print]

PMID:
31663411
4.

Liquid biopsies in renal cell carcinoma with focus on epigenome analysis.

Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Ann Transl Med. 2019 Sep;7(Suppl 6):S194. doi: 10.21037/atm.2019.07.30. No abstract available.

5.

An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.

Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F.

Expert Rev Mol Diagn. 2019 Oct 29:1-11. doi: 10.1080/14737159.2019.1684265. [Epub ahead of print]

PMID:
31640441
6.

Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma.

Santoni M, Heng DY, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R, Cimadamore A, Scarpelli M, Zaghloul MS, Battelli N, Montironi R.

Curr Drug Targets. 2019 Oct 17. doi: 10.2174/1389450120666191017113051. [Epub ahead of print]

PMID:
31625471
7.

Liquid biopsy in the clinical management of bladder cancer: current status and future developments.

Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L.

Expert Rev Mol Diagn. 2019 Oct 17:1-10. doi: 10.1080/14737159.2019.1680284. [Epub ahead of print]

PMID:
31608720
8.

Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples.

Volavšek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A.

Virchows Arch. 2019 Oct 7. doi: 10.1007/s00428-019-02666-x. [Epub ahead of print]

PMID:
31588959
9.

Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.

Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Ann Transl Med. 2019 Jul;7(Suppl 3):S137. doi: 10.21037/atm.2019.06.06. No abstract available.

10.

Prostate cancer pathology: What has changed in the last 5 years.

Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R.

Urologia. 2019 Sep 23:391560319876821. doi: 10.1177/0391560319876821. [Epub ahead of print]

PMID:
31545701
11.

Liquid biopsies in urological cancers: what we need to know before starting using them.

Franceschini T, Giunchi F, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Fiorentino M.

Expert Rev Mol Diagn. 2019 Sep 11:1-5. doi: 10.1080/14737159.2019.1665508. [Epub ahead of print] No abstract available.

PMID:
31509027
12.

Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.

Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H.

Expert Rev Mol Diagn. 2019 Sep 11:1-10. doi: 10.1080/14737159.2019.1665510. [Epub ahead of print]

PMID:
31498685
13.

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.

Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R.

Cancers (Basel). 2019 Aug 22;11(9). pii: E1225. doi: 10.3390/cancers11091225. Review.

14.

Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule.

Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, Cimadamore A, Lopez-Beltran A.

Hum Pathol. 2019 Aug 21;93:6-15. doi: 10.1016/j.humpath.2019.08.012. [Epub ahead of print]

PMID:
31442520
15.

Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology.

Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R.

Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30608-6. doi: 10.1016/j.eururo.2019.07.047. [Epub ahead of print] No abstract available.

PMID:
31420247
16.

Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution.

Bravi CA, Vertosick E, Tin A, Scuderi S, Fallara G, Rosiello G, Mazzone E, Bandini M, Gandaglia G, Fossati N, Freschi M, Montironi R, Briganti A, Montorsi F, Vickers A.

Eur Urol Oncol. 2018 Nov 24. pii: S2588-9311(18)30188-3. doi: 10.1016/j.euo.2018.10.007. [Epub ahead of print]

PMID:
31411978
17.

A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.

Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F.

Mol Diagn Ther. 2019 Oct;23(5):569-577. doi: 10.1007/s40291-019-00414-0. Review.

PMID:
31332726
18.

Editorial Comment.

Montironi R, Scarpelli M.

J Urol. 2019 Jul 8:10109701JU000057662492404c4. doi: 10.1097/01.JU.0000576624.92404.c4. [Epub ahead of print] No abstract available.

PMID:
31282273
19.

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G.

Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.

PMID:
31264522
20.

Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.

Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A.

Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.

PMID:
31240474
21.

Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer.

Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A.

APMIS. 2019 Aug;127(8):545-553. doi: 10.1111/apm.12973.

PMID:
31231851
22.

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.

Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R.

Future Oncol. 2019 Jul;15(19):2199-2202. doi: 10.2217/fon-2019-0217. Epub 2019 Jun 19. No abstract available.

PMID:
31213082
23.

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.

Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F.

Cancers (Basel). 2019 Jun 14;11(6). pii: E830. doi: 10.3390/cancers11060830. Review.

24.

MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia.

Magers MJ, Iczkowski KA, Montironi R, Grignon DJ, Zhang S, Williamson SR, Yang X, Wang M, Osunkoya AO, Lopez-Beltran A, Hes O, Eble JN, Cheng L.

Mod Pathol. 2019 Nov;32(11):1666-1674. doi: 10.1038/s41379-019-0297-6. Epub 2019 Jun 12.

PMID:
31189999
25.

Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?

Montironi R, Cheng L, Scarpelli M, Cimadamore A, Montorsi F, Lopez-Beltran A.

Eur Urol. 2019 Sep;76(3):e69-e72. doi: 10.1016/j.eururo.2019.05.035. Epub 2019 Jun 6. No abstract available.

PMID:
31176624
26.

BAP1 in solid tumors.

Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F.

Future Oncol. 2019 Jun;15(18):2151-2162. doi: 10.2217/fon-2018-0915. Epub 2019 Jun 4.

PMID:
31159579
27.

Editorial: Emerging Biomarkers in Genitourinary Tumors.

Montironi R, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L.

Front Oncol. 2019 Apr 26;9:326. doi: 10.3389/fonc.2019.00326. eCollection 2019. No abstract available.

28.

Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.

Montironi R, Zhou M, Magi-Galluzzi C, Epstein JI.

Eur Urol Oncol. 2018 May;1(1):21-28. doi: 10.1016/j.euo.2018.03.013. Epub 2018 May 15. Review.

PMID:
31100224
29.

Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges.

Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R.

Front Oncol. 2019 Apr 5;9:228. doi: 10.3389/fonc.2019.00228. eCollection 2019. No abstract available.

30.

Should We Perform Multiparametric Magnetic Resonance Imaging of the Bladder Before Transurethral Resection of Bladder? Time to Reconsider the Rules.

Panebianco V, Narumi Y, Barchetti G, Montironi R, Catto JWF.

Eur Urol. 2019 Jul;76(1):57-58. doi: 10.1016/j.eururo.2019.03.046. Epub 2019 Apr 15. No abstract available.

PMID:
31000355
31.

Microbiome and Cancers, With Focus on Genitourinary Tumors.

Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M.

Front Oncol. 2019 Mar 26;9:178. doi: 10.3389/fonc.2019.00178. eCollection 2019. No abstract available.

32.

Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.

Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F.

Clin Drug Investig. 2019 Jun;39(6):503-519. doi: 10.1007/s40261-019-00773-w. Review.

PMID:
30937824
33.

The Human Microbiota and Prostate Cancer: Friend or Foe?

Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G.

Cancers (Basel). 2019 Mar 31;11(4). pii: E459. doi: 10.3390/cancers11040459. Review.

34.

Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients.

Rocco B, Sighinolfi MC, Sandri M, Eissa A, Elsherbiny A, Zoeir A, Tadzia H, Palayapalayam H, Kameh D, Coelho R, Puliatti S, Zuccolotto P, Montironi R, Wiklund P, Micali S, Bianchi G, Patel V.

Urology. 2019 Jul;129:8-20. doi: 10.1016/j.urology.2019.03.019. Epub 2019 Mar 28. Review.

PMID:
30928608
35.

Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate.

Cheng L, Montironi R, Davidson DD, Wang M, Lopez-Beltran A, Zhang S.

Mol Carcinog. 2019 Jul;58(7):1272-1278. doi: 10.1002/mc.23009. Epub 2019 Mar 28.

PMID:
30920030
36.

Ex vivo fluorescence confocal microscopy: the first application for real-time pathological examination of prostatic tissue.

Puliatti S, Bertoni L, Pirola GM, Azzoni P, Bevilacqua L, Eissa A, Elsherbiny A, Sighinolfi MC, Chester J, Kaleci S, Rocco B, Micali S, Bagni I, Bonetti LR, Maiorana A, Malvehy J, Longo C, Montironi R, Bianchi G, Pellacani G.

BJU Int. 2019 Sep;124(3):469-476. doi: 10.1111/bju.14754. Epub 2019 Apr 17.

PMID:
30908852
37.

Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer.

Cimadamore A, Palagonia E, Piccinni P, Misericordia M, Galosi AB, Montironi R.

Urologia. 2019 Feb;86(1):35-38. doi: 10.1177/0391560319834494. Epub 2019 Feb 27.

PMID:
30808261
38.

Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.

Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R.

Curr Drug Metab. 2019;20(4):305-312. doi: 10.2174/1389200220666190225124352.

PMID:
30799789
39.

Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy.

Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Cancers (Basel). 2019 Feb 7;11(2). pii: E196. doi: 10.3390/cancers11020196. Review.

40.

Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study).

Antonelli A, Palumbo C, Noale M, Porreca A, Maggi S, Simeone C, Bassi P, Bertoni F, Bracarda S, Buglione M, Conti GN, Corvò R, Gacci M, Mirone V, Montironi R, Triggiani L, Tubaro A, Artibani W; Pros-IT CNR study group.

Urol Int. 2019;103(1):8-18. doi: 10.1159/000496980. Epub 2019 Feb 7.

PMID:
30731456
41.

Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.

Gevaert T, Eckstein M, Montironi R, Lopez-Beltran A.

Eur Urol. 2019 Jun;75(6):e162-e163. doi: 10.1016/j.eururo.2019.01.038. Epub 2019 Feb 1. No abstract available.

PMID:
30712970
42.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Oct;37(10):2147-2153. doi: 10.1007/s00345-019-02636-7. Epub 2019 Jan 22.

43.

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter.

Bianconi M, Cimadamore A, Faloppi L, Scartozzi M, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R.

Ther Adv Urol. 2019 Jan 8;11:1756287218815372. doi: 10.1177/1756287218815372. eCollection 2019 Jan-Dec. Review.

44.

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.

Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F.

Cells. 2019 Jan 11;8(1). pii: E43. doi: 10.3390/cells8010043. Review.

45.

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.

Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R.

Front Oncol. 2018 Dec 21;8:653. doi: 10.3389/fonc.2018.00653. eCollection 2018. Review.

46.

Staging of bladder cancer.

Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L.

Histopathology. 2019 Jan;74(1):112-134. doi: 10.1111/his.13734. Review.

PMID:
30565300
47.

Variants and new entities of bladder cancer.

Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L.

Histopathology. 2019 Jan;74(1):77-96. doi: 10.1111/his.13752. Review.

PMID:
30565299
48.

Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice.

Chovanec M, Albany C, Mego M, Montironi R, Cimadamore A, Cheng L.

Front Oncol. 2018 Nov 28;8:571. doi: 10.3389/fonc.2018.00571. eCollection 2018.

49.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436

Supplemental Content

Loading ...
Support Center